Study of treatment outcomes in ovarian-spread colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study follows women with colorectal cancer that has spread to the ovaries to see how care works in real life. It may help doctors understand which patients benefit most and how treatment choices affect outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer confirmed by lab testing (biopsy/pathology).
- Doctors have confirmed ovarian metastasis (ovary involvement) by scan and/or biopsy, even if other organs are involved.
- You are a woman age 18 or older.
- Your overall ability to do daily activities is limited but not severely (performance status 0–2).
- You can provide past medical records and any required scan/imaging data (or you may not have a measurable tumor to measure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
This study looks at how early-onset colorectal cancer treatment affects reproductive and sexual health over time. It asks eligible people to complete questionnaires so researchers can understand and possibly improve care during and after treatment.
This study looks at metastatic ovarian cancer by analyzing many types of patient data (from “multi-omics,” which means different kinds of lab and biological information). It may help doctors better understand the disease and improve future care.
This study looks at gut bacteria in people with colorectal cancer that has spread (metastatic). It aims to find patterns in the bacteria that may help doctors choose better treatments.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
This study looks for biological markers that can help predict where colorectal cancer might spread. It aims to find patterns that could guide future treatment decisions. By understanding these markers, doctors may be able to detect and manage cancer recurrence earlier.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.